GlassScriptPhysician profile
Daniel H Tobias
NPI 1508830746
$11,261.90
in general payments reported to CMS, 2019-2025
36 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $3,348 · 2021: $2,777 · 2022: $13.33 · 2023: $2,586 · 2024: $1,022 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,492 · Consulting Fee: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,492.17 |
| Consulting Fee | $1,515.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $4,292.00 | 2021-2023 | |
| Abbvie INC. | $3,166.35 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $979.92 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $606.85 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $439.20 | 2019-2025 | Lynparza |
| Glaxosmithkline, LLC. | $348.56 | 2020-2025 | Jemperli, Zejula |
| Pfizer INC. | $282.97 | 2023-2025 | |
| Mirati Therapeutics, INC. | $153.17 | 2023-2024 | Krazati |
| Incyte Corporation | $81.19 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Foundation Medicine, INC. | $61.17 | 2023 | |
| Kerecis Limited | $59.36 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Agios Pharmaceuticals, INC. | $54.84 | 2025 | Pyrukynd |
| Novartis Pharmaceuticals Corporation | $52.85 | 2024-2025 | |
| Davol INC. | $52.03 | 2025 | Arista |
| Tersera Therapeutics LLC | $51.00 | 2023-2024 | Zoladex |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $50.91 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.83 | 2023-2025 | |
| Janssen Biotech, INC. | $49.98 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $41.09 | 2023 | Xospata |
| Myriad Genetic Laboratories, INC. | $36.97 | 2023-2024 | Myrisk |
| Acera Surgical, INC. | $36.86 | 2023 | Restrata Wound Matrix |
| Karyopharm Therapeutics INC. | $36.22 | 2023 | Xpovio |
| Genzyme Corporation | $34.99 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.26 | 2024 | Vpriv |
| Ethicon US, LLC | $22.37 | 2019 | |
| Exelixis INC. | $19.57 | 2025 | Cabometyx |
| Caris Mpi, INC. | $19.50 | 2025 | Mi Cancer Seek |
| Cumberland Pharmaceuticals, INC. | $19.00 | 2025 | Sancuso |
| Pharmaessentia USA Corporation | $18.79 | 2025 | Besremi |
| Deciphera Pharmaceuticals INC. | $18.72 | 2024 | Qinlock, Tgct |
| Lilly USA, LLC | $18.45 | 2024 | Jaypirca, Retevmo, Verzenio |
| Stemline Therapeutics INC. | $17.09 | 2025 | Orserdu |
| Recordati_rare_diseases_inc. | $16.82 | 2024 | Sylvant |
| Seagen INC. | $16.46 | 2023 | Tukysa |
| Pharmacosmos Therapeutics INC. | $15.99 | 2023 | Monoferric |
| Boston Scientific Corporation | $13.57 | 2025 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tobias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.